Since 2018, Stenocare has been the leading provider of medical cannabis oil products for the Danish Pilot Programme and has expanded into five other markets with approved products. Stenocare operates today in Denmark, Sweden, Norway, Germany, the United Kingdom, and Australia. The company consistently analyzes market opportunities and collects feedback from doctors to evaluate the product pipeline, fulfilling its mission to provide prescription-based medical cannabis products for patient treatment. See the table attached to this press release for more details.

ASTRUM Oil: Since 2019, the company has invested in qualifying and developing the new and innovative ASTRUM Oil product. Through a pharmacokinetic study with dogs, it has documented improved bioavailability in the blood, enhanced uniformity of uptake, and reduced time for maximum uptake. Bringing true innovation to the market is a multi-year investment, and the Australian market is the first to benefit from this new product in Q3 2024. Stenocare continues its efforts in developing ASTRUM Oil for new markets.

High CBD Oil: Stenocare has received feedback from doctors indicating a therapeutic need for a CBD Oil product with very high potency. Having successfully completed the concept stage and R&D stage for this product candidate, Stenocare has initiated the process of seeking approval for sales from the Medicines Agency.

In total, Stenocare has 13 medical cannabis oil products approved for sales across its six markets. Each product has been reviewed and approved by the individual medicines agencies for their local market.